Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.60 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.49 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30460119 | 1.00 | CRBN (0.60) | CRBNIKZF1IKZF2CSNK1A1GSPT1 | |
| SCHEMBL23876476 | 0.90 | CRBN (0.64) | CRBNIKZF1IKZF2 | |
| SCHEMBL25212437 | 0.89 | CRBN (0.60) | CRBNIKZF1IKZF2CSNK1A1DDB1 | |
| SCHEMBL29450095 | 0.89 | CRBN (0.60) | CRBNIKZF1IKZF2CSNK1A1DDB1 | |
| SCHEMBL31116980 | 0.89 | CRBN (0.60) | CRBNIKZF1IKZF2CSNK1A1DDB1 | |
| SCHEMBL25236602 | 0.89 | CRBN (0.60) | CRBNIKZF1IKZF2 | |
| Hydrochloric Acid SCHEMBL30496965 | 0.88 | CRBN (0.58) | CRBNIKZF1IKZF2CSNK1A1DDB1 | |
| Hydrochloric Acid SCHEMBL25234527 | 0.88 | CRBN (0.58) | CRBNIKZF1IKZF2CSNK1A1DDB1 | |
| SCHEMBL24816631 | 0.87 | CRBN (0.53) | CRBNIKZF1IKZF2CSNK1A1GSPT1 | |
| SCHEMBL22557008 | 0.87 | CRBN (0.69) | CRBNIKZF1IKZF2CSNK1A1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | claimed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | claimed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | disclosed |